%0 Journal Article
%T Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
%A Laokulrath N
%A Gudi M
%A Salahuddin SA
%A Chong APY
%A Ding C
%A Iqbal J
%A Leow WQ
%A Tan BY
%A Tse G
%A Rakha E
%A Tan PH
%J Histopathology
%V 85
%N 3
%D 2024 Sep 6
%M 38845396
%F 7.778
%R 10.1111/his.15213
%X Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.